Article in Cancer research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
31 authors at 1 institution in 1 country.
Felicia GomezDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0003-4884-7510
Bryan FiskDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-7648-1360
Joshua F McMichaelMcDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-0197-2245
Matthew MosiorDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-9704-408X
Jennifer A FoltzDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0001-9158-3464
Zachary L SkidmoreDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0003-1928-7139
Eric J DuncavageDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0003-4199-8906
Christopher A MillerDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0003-4266-6700
Haley AbelDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0003-3110-8041
Yi-Shan LiDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0001-6070-8375
David A Russler-GermainDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0003-1009-2247
Kilannin KrysiakDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-6299-9230
Marcus P WatkinsDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-1224-3478
Cody A RamirezDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0001-5598-0876
Alina SchmidtDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0001-7317-7868
Fernanda Martins RodriguesDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-2140-0690
Lee TraniMcDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0001-9858-5833
Ajay KhannaDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0001-7800-5512
Julia A WagnerDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-2438-3873
Robert S FultonMcDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.ORCID 0009-0006-6820-3404
Catrina C FronickMcDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-2766-9551
Michelle D O'LaughlinMcDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0001-7678-3783
Timothy SchappeDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0009-0002-1391-1519
Amanda F CashenDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0001-6809-4566
Neha Mehta-ShahDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0001-5744-0670
Brad S KahlDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0003-0459-6609
Jason WalkerMcDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0001-7547-5789
Nancy L BartlettDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0001-8470-394X
Malachi GriffithDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-6388-446X
Todd A FehnigerDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-8705-2887
Obi L GriffithDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-0843-4271
Washington University in St. Louis · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Washington University Paul Calabresi K12 Career Development Award for Clinical OncologyK12CA167540 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio, Ramaswamy Govindan · 2012 to 2026
$11.7M
Standardized and Genome-Wide Clinical Interpretation of Complex Genotypes for Cancer Precision MedicineU24CA237719 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2019 to 2023
$3.8M
Informatics tools for identification, prioritization and clinical application of neoantigensU01CA248235 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, MALACHI · 2020 to 2022
$1.3M
DEVELOPMENT OF INFORMATICS RESOURCES FOR INTERPRETATION OF CLINICALLY ACTIONABLE VARIANTS IN CANCERU01CA209936 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2016 to 2018
$1.0M
Deep Sequencing of Relapse and Refractory Hodgkin Lymphoma Genomes: A Study of Tumor Biology and EvolutionK22CA266743 · NCI · WASHINGTON UNIVERSITY · PI GOMEZ, FELICIA · 2023 to 2025
$583k
DEFINING THE REGULATORY, NON-CODING, MUTATIONAL LANDSCAPE OF BREAST CANCERK22CA188163 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2014 to 2016
$515k
INTEGRATED ANALYSIS & INTERPRETATION OF WHOLE GENOME, EXOME & TRANSCRIPTOME SEQUENCE DATA IN CANCERK99HG007940 · NHGRI · WASHINGTON UNIVERSITY · PI GRIFFITH, MALACHI · 2015 to 2016
The malignant Hodgkin and Reed Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) are scarce in affected lymph nodes, creating a challenge to detect driver somatic mutations. As an alternative to cell purification techniques, we hypothesized that ultra-deep exome sequencing would allow genomic study of HRS cells, thereby streamlining analysis and avoiding technical pitfalls. To test this, 31 cHL tumor/normal pairs were exome sequenced to approximately 1,000× median depth of coverage. An orthogonal error-corrected sequencing approach verified >95% of the discovered mutations. We identified mutations in genes novel to cHL including: CDH5 and PCDH7, novel stop gain mutations in IL4R, and a novel pattern of recurrent mutations in pathways regulating Hippo signaling. As a further application of our exome sequencing, we attempted to identify expressed somatic single-nucleotide variants (SNV) in single-nuclei RNA sequencing (snRNA-seq) data generated from a patient in our cohort. Our snRNA analysis identified a clear cluster of cells containing a somatic SNV identified in our deep exome data. This cluster has differentially expressed genes that are consistent with genes known to be dysregulated in HRS cells (e.g., PIM1 and PIM3). The cluster also contains cells with an expanded B-cell clonotype further supporting a malignant phenotype. This study provides proof-of-principle that ultra-deep exome sequencing can be utilized to identify recurrent mutations in HRS cells and demonstrates the feasibility of snRNA-seq in the context of cHL. These studies provide the foundation for the further analysis of genomic variants in large cohorts of patients with cHL. SIGNIFICANCE: Our data demonstrate the utility of ultra-deep exome sequencing in uncovering somatic variants in Hodgkin lymphoma, creating new opportunities to define the genes that are recurrently mutated in this disease. We also show for the first time the successful application of snRNA-seq in Hodgkin lymphoma and describe the expression profile of a putative cluster of HRS cells in a single patient.
Indexed as
Hodgkin DiseaseHigh-Throughput Nucleotide SequencingHumansMutationReed-Sternberg CellsRNA, Small NuclearRNA, Small Nuclear
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma. · full record | OpenQuestion